Dr. Heinrich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-6594
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 1988 - 1991- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1984 - 1988
Johns Hopkins University School of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 2023 - 2025
ID State Medical License 2022 - 2025
OR State Medical License 1985 - 2025
WA State Medical License 2022 - 2025
AK State Medical License 2024 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Portland Monthly Magazine Castle Connolly, 2011
- Join now to see all
Clinical Trials
- S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Start of enrollment: 2003 Oct 01
- Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Start of enrollment: 2001 Feb 01
- Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 813 citationsIn vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.Thomas O'Hare, Denise K. Walters, Eric P. Stoffregen, Taiping Jia, Paul W. Manley
Cancer Research. 2005-06-01 - 16 citationsAsciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.Michael J Mauro, Timothy P Hughes, Dong-Wook Kim, Delphine Rea, Jorge E Cortes
Leukemia. 2023-05-01 - 188 citationsMutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemiaBianca F. Goemans, Ch. M. Zwaan, M. Miller, Martin Zimmermann, Amy Harlow
Leukemia. 2005-09-01
Journal Articles
- Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical AdvancesM C Heinrich, S George, M L Hemming, Annals of Oncology
Lectures
- Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Two Studies Seek to Go Beyond the GIST of Intestinal Tract CancerAugust 24th, 2021- The Life Raft Group, a Non-Profit Supporting Patients with GIST Cancer, Announces Members of the 2021 Medical Advisory BoardMarch 16th, 2021
FDA Approves Avapritinib for Resectable or Metastatic Gastrointestinal Stromal TumorJanuary 10th, 2020- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
